FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine
Dannel Yeo, Hong He, Oneel Patel, Andrew M Lowy, Graham S Baldwin, Mehrdad Nikfarjam
BMC Cancer | BMC | Published : 2016
Related Projects (2)
Awarded by National Health and Medical Research Council of Australia
Awarded by National Institutes of Health
We thank Prof. Ian Gordon, Statistical Consulting Centre, The University of Melbourne, Parkville, Australia for his assistance with statistical analysis, and Chelsea Dumesny, Nhi Huynh, and Marie Laval for skilled assistance with the animal experiments. D.Y. is supported by Australian Rotary Health (The Ian Loxton Pancreatic Cancer Research PhD Scholarship).This work was supported by National Health and Medical Research Council of Australia Grants [508908 to H.H] and [1020983 to G.S.B]; National Institutes of Health [CA155620-01 to A.M.L]; Austin Hospital Medical Research Foundation (M.N); and Sir Edward Dunlop Foundation Grant (M.N).